Pharmacological treatment of the pathogenetic defects in Type 2 Diabetes. The randomized multi-centre South Danish Diabetes study (SDDS) by Gram, Jeppe et al.
Pharmacological Treatment of the
Pathogenetic Defects in Type 2 Diabetes
The randomized multicenter South Danish Diabetes Study
JEPPE GRAM, MD, PHD1
JAN ERIK HENRIKSEN, MD, PHD2
ELLEN GRODUM, MD3
HENNING JUHL, MD, DMSC4
TONY BILL HANSEN, MD, PHD5
CHRISTIAN CHRISTIANSEN, MD, PHD1
KNUD YDERSTRÆDE, MD, PHD2
HANS GJESSING, MD, DMSC3
HENRIK M. HANSEN, MD4
VIBE VESTERGAARD2
JØRGEN HANGAARD, MD, PHD5
HENNING BECK-NIELSEN, MD, DMSC2
OBJECTIVE— To determine the effect of treatment with insulin aspart compared with NPH
insulin, together with metformin/placebo and rosiglitazone/placebo. The hypothesis was that
combined correction of major pathogenetic defects in type 2 diabetes would result in optimal
glycemic control.
RESEARCH DESIGN ANDMETHODS— This study was a 2-year investigator-driven
randomized partly placebo-controlled multicenter trial in 371 patients with type 2 diabetes on at
least oral antiglycemic treatment. Patients were assigned to one of eight treatment groups in a
factorial design with insulin aspart at mealtimes versus NPH insulin once daily at bedtime,
metformin twice daily versus placebo, and rosiglitazone twice daily versus placebo. The main
outcome measurement was change in A1C.
RESULTS— A1C decreased more in patients treated with insulin aspart compared with NPH
(0.41  0.10%, P  0.001). Metformin decreased A1C compared with placebo (0.60 
0.10%, P  0.001), as did rosiglitazone (0.55  0.10%, P  0.001). Triple therapy (rosigli-
tazone, metformin, and any insulin) resulted in a greater reduction in A1C than rosiglitazone
plus insulin (0.50  0.14%, P  0.001) and metformin plus insulin (0.45  0.14%, P 
0.001). Aspart was associated with a higher increase in body weight (1.6 0.6 kg, P 0.01) and
higher incidence of mild daytime hypoglycemia (4.9  7.5 vs. 1.7  5.4 number/person/year,
P  0.001) compared with NPH.
CONCLUSIONS— Insulin treatment of postprandial hyperglycemia results in lower A1C
than treatment of fasting hyperglycemia, at the expense of higher body weight and hypoglycemic
episodes. However, insulin therapy has to be combined with treatment of both peripheral and
liver insulin resistance to normalize blood glucose, and in this case, the insulin regimen is less
important.
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Only a few long-term studies have fo-cused on different insulin treatmentmodalities and the blinded combi-
nation with different oral antidiabetic
drugs. Theoretically, the best antiglyce-
mic treatment is to aim at restoring the
main pathophysiological defects in type 2
diabetes: decreased first-phase insulin se-
cretion, peripheral insulin resistance, and
elevated hepatic gluconeogenesis. These
defects may theoretically be partly cor-
rected pharmacologically by a rapid-
acting insulin analog before meals,
mimicking the lacking postprandial insu-
lin peak; by an insulin sensitizer improv-
ing peripheral insulin action; and by
metformin reducing hepatic glucose pro-
duction (1).
The South Danish Diabetes Study is
an investigator-driven 2-year randomized
controlled clinical trial testing the follow-
ing hypotheses: 1) the more physiological
insulin profile obtained with insulin as-
part treatment at meals (without long-
acting insulin at night) is more effective
than the conventional use of NPH insulin
given once daily at bedtime; 2) addition of
metformin or rosiglitazone to insulin
treatment will further improve the glu-
cose control; and 3) combination of insu-
lin, metformin, and rosiglitazone (triple
therapy) will result in the most optimal
glycemic control.
RESEARCH DESIGN AND
METHODS
Subjects
Patients aged 30–70 years with type 2 di-
abetes were included at eight hospital
centers in the southern region of Den-
mark. Eligible patients had the following
characteristics: BMI 25 kg/m2 and fast-
ing plasma C-peptide300 pmol/l, treat-
ment for at least 3 months with stable
doses of oral antidiabetic medications
and/or insulin, and A1C7.0%. Prior in-
sulin treatment could be any insulin reg-
imen, but most subjects were treated with
long-acting insulin. The exclusion criteria
were congestive heart failure, impaired
renal function, and known intolerance to
metformin or rosiglitazone and/or treat-
ment with glitazones 30 days before
randomization.
Study design
A total of 450 subjects were included. Af-
ter a 4-week run-in period, all 371 eligible
patients were randomized to one of eight
treatment groups in a factorial design
with NPH insulin versus insulin aspart,
metformin versus placebo, and rosiglita-
zone versus placebo (Fig. 1). After a
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3-month insulin titration period, patients
were followed every 3 months for 2 years.
Intervention
All prior antidiabetic treatments were
stopped. Patients allocated to NPH insu-
lin at bedtime measured fasting blood
glucose (FBG) every day and received a
starting dose of 12 IU. Patients already on
insulin received 50% of their prior total
daily dose. In a treat-to-target algorithm,
insulin dose was increased by 2 IU if FBG
was 5.6 mmol/l, 4 IU if FBG was 8.0
mmol/l, and 6 IU if FBG was 12.0
mmol/l on 3 consecutive days until FBG
was 5.5 mmol/l and A1C was 6.5%,
provided no unacceptable hypoglycemic
episodes.
Patients allocated to insulin aspart
measured postprandial blood glucose
three times daily 90 min after each main
meal and received a starting dose of 4 IU
just before each main meal. Patients al-
ready on insulin received 50% of their
prior total daily dose divided into three
doses. In a treat-to-target algorithm, insu-
lin dose at each meal was increased by 1
IU if postprandial blood glucose was
7.5 mmol/l, 2 IU if postprandial blood
glucose was 9.0 mmol/l, 3 IU if post-
prandial blood glucose was 11.0
mmol/l on 3 consecutive days until post-
prandial blood glucose was 7.5 mmol/l
and A1C was 6.5%, provided no limit-
ing hypoglycemic episodes.
After a 3-month intensive insulin ti-
tration period, patients were instructed to
continue using the algorithm, but daily
blood glucose monitoring was not re-
quested if the treatment goals were
achieved.
Metformin or placebo was given from
the start of the study as one tablet of 500
mg twice daily during the first 4 weeks
succeeded by two tablets twice daily, and
rosiglitazone or placebo was given as one
tablet of 4 mg once daily in the first 8
weeks succeeded by one tablet twice
daily.
An increase of A1C by 2.0% (abso-
lute) or A1C exceeding 12.0% (absolute),
measured twice over a 6-month period,
were considered treatment failures.
Biochemical and clinical
measurements
A1C was measured every 3 months. Pa-
tients monitored capillary blood glucose
daily (One Touch Ultra, LifeScan) and
performed two eight-point 24-h glucose
profiles before each visit.
Safety assessments
Any adverse event was recorded. Hypo-
glycemic episodes were registered by the
patients every day in a diary and were de-
fined as either mild (blood glucose 2.8
mmol/l and symptoms consistent with
hypoglycemia) or moderate (blood glu-
cose2.8 mmol/l with or without symp-
toms). Serious hypoglycemia was defined
as any hypoglycemic episode requiring
assistance.
Figure 1—Enrollment and outcomes. The number of participants enrolled in the study is shown. The intention-to-treat (ITT) population included
369 patients, since 2 were withdrawn before first efficacy evaluation. The per-protocol population included 251 patients. asp, aspart.
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Protocol oversight
The protocol was in accordance with the
Declaration of Helsinki and approved by
the regional committee on Biomedical Re-
search Ethics (M-2417-02). GCP moni-
toring was performed by the local GCP
unit and a contract company. Statistical
analysis was performed by an indepen-
dent statistician. The statistical analysis
plan was completed before the database
was locked and unblinded. Safety data
were reviewed unblinded during the
study by an independent academic diabe-
tologist. The randomization code was de-
veloped by an independent statistician
using a computer random number gener-
ator to select random blocks of eight. Ran-
domization to insulin type was open,
whereas allocation to other treatments
was double-blinded.
Sample size
The primary outcome variable was A1C.
Assuming a minimal relevant difference
between the two insulin treatment arms of
0.4% and a standard deviation of 1.15, a
total of 176 in each of the pooled insulin
treatment groups were calculated as nec-
essary to provide the study with 90%
power to detect a difference of this mag-
nitude (P  0.05). Assuming a dropout
rate of 10%, a total of around 400 subjects
were planned to be included.
Statistical analysis
The factorial design of the study allowed
us to compare the effect of each compo-
nent in the antidiabetic treatment evalu-
ated but not to compare every eight
treatment groups with each other. In ac-
cordance with the hypothesis, we com-
pared insulin aspart with NPH insulin,
determined the effect of adding met-
formin and/or rosiglitazone to insulin
treatment, and paid special attention to
the effect of triple therapy (insulin plus
metformin plus rosiglitazone). All data
are presented as means  SD or SEM.
Statistical analysis was on an intention-to-
treat basis and last observation carried
forward. A per-protocol analysis for the
primary end point was also performed.
The efficacy analysis (A1C) was per-
formed by ANCOVA on changes from
baseline to the mean of A1C for 12–24
months (inclusive) with the three treat-
ments and center as fixed main effects and
baseline A1C value as a covariate. The pa-
tient was a random effect in the model.
First-order interactions and each of the
following baseline covariates were also in-
cluded as fixed effects in the statistical
model: fasting plasma C-peptide, interac-
tion between fasting plasma C-peptide
and treatment, and previous insulin use.
Treatment differences in the number of
patients with A1C7.0% were tested us-
ing logistic linear regression, with the
three treatments and their interactions in-
cluded in the model. Plasma glucose pro-
files were analyzed by a repeated-
measures ANOVA, performed after
logarithmic transformation. Hypoglyce-
mic episodes were analyzed using a gen-
eralized linear model based on the
negative binomial distribution. The num-
ber of patients experiencing at least one
hypoglycemic episode was compared
with the groups using the Fisher exact
test.
RESULTS
Patient characteristics
There were no clinically important differ-
ences in baseline demographic and clini-
cal characteristics between treatment
groups in the study population (Table 1).
Glycemic control
The overall difference between the reduc-
tion in A1C between the aspart and NPH
groups (n  175 vs. 182) was 0.41 
0.10% (P  0.001) (i.e., insulin aspart
was associated with a larger reduction in
A1C than observed with NPH insulin).
Moreover, in all patients, metformin ver-
sus placebo treatment (n  179 vs. 178)
was associated with a decrease in A1C of
0.60 0.10% (P 0.001) and rosigli-
tazone versus placebo treatment (n 179
vs. 178) with a decrease of 0.55 
0.10% (P  0.001). When only the per-
protocol population was examined, simi-
lar results were observed.
As illustrated in Fig. 2 and Table 2,
A1C decreased in all eight study groups
but most during addition of oral antidia-
betic agents to insulin. There was no dif-
ference between the two triple therapy
groups (aspart versus NPH plus met-
formin and rosiglitazone) (P 0.15). Tri-
ple therapy, with any insulin, resulted in
the greatest reduction in A1C compared
with any insulin plus placebo (1.14 
0.13%, P  0.001), any insulin plus ros-
iglitazone (0.50  0.14%, P  0.001),
and any insul in plus met formin
(0.45  0.14%, P  0.001).
The percentages of patients reaching
the A1C target of 7.0% in all patients
were as follows: aspart versus NPH, 48 vs.
42% (P  0.25); metformin versus pla-
cebo, 56 vs. 34% (P  0.001); and ros-
iglitazone versus placebo, 56 vs. 34%
(P  0.002). The percentages reaching
the same goal in the two triple therapy
groups, aspart versus NPH, were 64 ver-
sus 67% (P  0.15).
Self-monitored plasma glucose pro-
files were significantly lower using insulin
aspart versus NPH insulin (P  0.005),
metformin versus placebo (P  0.001),
and rosiglitazone versus placebo (P 
0.001) (supplementary Fig. 1, available
in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc10-
0531/DC1).
Insulin dose
Insulin dose was highest in the groups
treated by insulin alone, whereas addition
of either metformin or rosiglitazone re-
sulted in a decrease in total daily insulin
dose and addition of both metformin and
rosiglitazone resulted in the lowest insu-
lin dose (Table 2).
Hypoglycemia
Overall, more patients using insulin as-
part reported at least one hypoglycemic
episode compared with the patients using
NPH insulin (160 vs. 137, P  0.005),
with no difference between the met-
formin and placebo groups (143 vs. 154,
NS) or between the rosiglitazone and pla-
cebo groups (150 vs. 147, NS).
During the last year of intervention,
treatment with insulin aspart was associ-
ated with more total daytime hypoglyce-
mic episodes compared with NPH insulin
(6.7  9.9 vs. 1.9  5.7, P  0.001).
However, the total number of nocturnal
hypoglycemic episodes was higher in the
NPH insulin group than in the aspart
group (3.0  6.3 vs. 0.5  2.1, P 
0.001). During the entire intervention pe-
riod, eight patients in the NPH insulin
group experienced eight episodes of se-
vere hypoglycemia and 11 patients in the
aspart group experienced 13 episodes.
Body weight
Body weight increased in all treatment
groups (Table 2). Overall, insulin aspart
was associated with an increase in body
weight of 1.6 0.6 kg (P 0.009) com-
pared with NPH insulin, rosiglitazone
with an increase of 2.3  0.6 kg (P 
0.001) compared with non-rosiglitazone
treatment, and metformin with a decrease
in body weight of 2.8  0.6 kg (P 
0.001) compared with non-metformin
treatment.
Gram and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 34, NUMBER 1, JANUARY 2011 29
Adverse events
When the NPH and insulin aspart groups
were compared, statistically significant
more adverse events were found in the
insulin aspart group (861 vs. 723) (P 
0.003). There was no statistically signifi-
cant differences between specific adverse
events between the two groups and no
difference in number of serious adverse
events was found (51 vs. 56) or death (4
vs. 0, Fig. 1). No difference in adverse
events, either in adverse event or in seri-
ous adverse event was found comparing
the metformin and placebo group (seri-
ous adverse event: 53 vs. 54) or the ros-
iglitazone and placebo group (serious
adverse event: 54 vs. 56). (The details of
the specific adverse events can be found
in supplementary Table 1).
CONCLUSIONS
Effect of insulin treatment on blood
glucose control
The study provides evidence that mono-
therapy with NPH insulin at bedtime is
not an optimal way of treating hypergly-
cemia in type 2 diabetes, although this
treatment has been recommended until
recently (2,3). It could be argued that a
long-acting insulin analog would have
performed better, but in the LANMET
treat-to-target trial comparing NPH insu-
lin and insulin glargine (4), the two insu-
lin treatments combined with metformin
gave identical A1C values.
Treatment with insulin aspart re-
sulted in better blood glucose control
than NPH insulin, even though aspart was
not combined with any basal insulin. The
difference between aspart and NPH treat-
ment on A1C disappeared when com-
bined with metformin or both metformin
and rosiglitazone. The benefit of prandial
insulin treatment was also found during
the first year of the 4T study (5) but dis-
appeared in the 2-year follow-up (6)
when basal-bolus insulin treatments were
combined.
Recently, another study showed a
nonsignificant difference in favor of insu-
lin lispro compared with insulin glargine
of0.2% in A1C (7), which is supported
by an older study also comparing insulin
lispro with insulin glargine and showing a
significant reduction in A1C of 0.8% in
the prandial insulin lispro group (8).
It has been shown that postprandial
hyperglycemia is an important determi-
nant for the level of A1C, especially the
closer the A1C is to the treatment goal (9).
This result supports the fact that treat-T
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ment aimed at replacing first-phase insu-
lin secretion is important. Furthermore,
an advantage of the solely prandial insulin
regimens is that, during the night, pa-
tients are only covered by endogenous in-
sulin production and therefore do not
develop nocturnal hypoglycemia (10).
Effect of treatment with oral
hypoglycemic agents on blood
glucose control
Both metformin and rosiglitazone as add-
ons to insulin treatment improved the
metabolic control significantly and low-
ered the insulin dose, indicating that it is
important not only to give insulin, but
also to improve insulin action in periph-
eral tissues and in the liver. Several previ-
ous studies have addressed the issue of
combining insulin and metformin treat-
ment and have indicated a clear advantage
of doing so (11–15).
Most studies on combination treat-
ment with glitazone and insulin have
found an improvement in glycemic con-
trol compared with insulin given in
monotherapy (15–19). Moreover, glita-
zones also have an insulin-sparing effect
(15–18). However, the combination
treatment is associated with an increase in
body weight (15–19).
Effect of triple therapy treatment on
blood glucose control
The most optimal treatment with respect
to glycemic control in our study was triple
therapy using insulin, rosiglitazone, and
metformin. Around 66% of our patients
treated with triple therapy reached the
A1C target of7.0%. A similar high pro-
portion of responders have only rarely
been achieved in other randomized trials
of insulin treatment in type 2 diabetes be-
sides in the advanced insulin regimens
groups in the 4T trial (6). The same com-
bination therapy has been investigated in
a few short-term studies previously
(10,20–23).
The triple concept gave identical re-
sults no matter what insulin regimen was
used. The reason for this seems to be that
insulin aspart only replaces first-phase in-
sulin secretion and NPH insulin only
basal insulin secretion, thus not covering
the full 24-h period adequately. Based on
the 4T follow-up study (6), it may be
speculated that the combined effect of
prandial aspart and basal NPH insulin is
the best treatment.
Hypoglycemia
The overall numbers of clinically relevant
hypoglycemic episodes were low, being
comparable to the numbers reported in
the 4T trial (5). Despite the surplus of hy-
poglycemic episodes in the insulin aspart
group, the majority of episodes were dur-
ing the daytime, which may be more ac-
ceptable than nocturnal episodes seen
more often in the NPH insulin group.
Moreover, it can be speculated if the mea-
surements of postprandial glucose con-
centration thrice daily in the aspart
groups made this group more prone to
Figure 2—Mean  SE observed A1C values during the 2-year intervention period in patients randomized to treatment with either NPH insulin
(black symbols) or insulin aspart (open symbols) in combination with placebo (A, P 0.001), metformin (B, P 0.15), rosiglitazone (C, P 0.02),
or metformin and rosiglitazone (D, P  0.15).
Gram and Associates
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register hypoglycemic episodes during
the day.
Body weight
It is well known that improvement in
blood glucose control often increases
body weight. Insulin treatment in combi-
nation with glitazones may result in more
weight gain than other treatments (24).
However, interestingly, if we compared
the weight gain using triple therapy with
insulin, metformin, and rosiglitazone, it
was comparable to that observed with in-
sulin treatment alone, as also seen in the
4T study (5).
Adverse effects
There is no clear explanation for the in-
creased number of adverse events found
in the aspart-treated groups. It was seen in
all system organ classes but not in the
number of serious adverse events or
death. All adverse events were noted by
the patients in their diabetes diary, and it
may be speculated if the thrice-daily mea-
surement and notation of blood glucose
made them more prone to report adverse
events than the NPH group only measur-
ing FBG.
The recently published ACCORD,
ADVANCE, and VADT studies show no
benefit in relation to reduction in cardio-
vascular disease risk with improvements
in glycemic control. It is important to re-
alize that our study was not a study de-
signed to address this issue. Moreover, it
seems from the recent follow-up study of
the UK Prospective Diabetes Study (25)
that normalization of glycemic control
should be obtained when the diagnosis of
type 2 diabetes is made and further that
the benefits of improved glycemic control
are maintained many years after the study
intervention (25).
In conclusion, treatment of postpran-
dial hyperglycemia with insulin aspart re-
sults in lower A1C than treatment of
fasting hyperglycemia with NPH insulin,
but with more side effects. For optimal
treatment, insulin must be combined
with treatment of both peripheral and
liver insulin resistance, and, in this case,
the choice of insulin regimen is less
important.
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